article thumbnail

The Benefits of Cannabis in the Treatment of Myasthenia Gravis

United Patients Group

The Benefits of Cannabis in the Treatment of Myasthenia Gravis Introduction Myasthenia gravis ( MG ) is a rare autoimmune disease that affects the nerves and muscles. Doctors usually treat MG with thymectomies, immunomodulating drugs, acetylcholinesterase inhibitors and IV immunoglobulin treatments. This cannabinoid is called THCa.

Treatment 123
article thumbnail

Washington Cannabis Update: Non-CBD Cannabinoid Additives

Canna Law Blog

The Washington State Liquor and Cannabis Board (“LCB”) has clarified what cannabinoid additives are allowed in Cannabis products in WA. Cannabinoids. The cannabis sativa plant produces over 100 cannabinoids , not all of which have psychoactive or intoxicating effects. Adding cannabinoids to Washington cannabis products.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Cannabinoids and Cannabinoid Receptors: What Are They?

United Patients Group

Introduction The endocannabinoid system (ECS) is a group of cannabinoid receptors located throughout the body, but particularly in the brain and central nervous system, that interact with cannabis compounds. There are two major cannabinoid receptors: CB1 and CB2. There are two major cannabinoid receptors: CB1 and CB2.

article thumbnail

The Impact of Medical Marijuana on Mental Health

MMJ Recs

Through community outreach, social media campaigns, educational seminars, and mental health screenings, the month seeks to empower individuals to seek help when needed, cultivate supportive environments, and advocate for policies that promote mental health equity and access to care.

Marijuana 105
article thumbnail

Jason Straw: Medical Cannabis Policy, ISNA 2020 Conference

Cannabis Law Report

In Indianapolis on January 29, a quiet, eager audience of nurses give their rapt attention to Jason Straw as he takes center stage at the 2020 ISNA Policy Conference. ISNA 2020 POLICY CONFERENCE AGENDA, Jason Straw- Cannabis Policy. ISNA 2020 POLICY CONFERENCE AGENDA, Jason Straw- Cannabis Policy. PURPOSE : .

Policy 105
article thumbnail

ICRS 2023: Report from Toronto

Project CBD

I counted over 175 talks and posters at the 33rd annual gathering of the International Cannabinoid Research Society (ICRS), which convened in Toronto at the end of June. In accordance with longstanding ICRS policy, all speakers presented new findings and data that had not yet been published in a peer-reviewed journal.

article thumbnail

Australia – Policy Analysis: Medicinal cannabis and driving: the intersection of health and road safety policy – “there is little evidence to justify the differential treatment of medicinal cannabis patients, compared with those taking other prescription medications”

Cannabis Law Report

We conclude that in medical-only access models there is little evidence to justify the differential treatment of medicinal cannabis patients, compared with those taking other prescription medications with potentially impairing effects. Access to treatment. Daniel Perkins a b Hugh Brophy a Iain S. Medicinal cannabis. Road safety.